Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Holdings Boosted by Nuveen Asset Management LLC

Nuveen Asset Management LLC boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 10.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 524,579 shares of the biotechnology company's stock after acquiring an additional 50,379 shares during the quarter. Nuveen Asset Management LLC owned about 0.55% of Sarepta Therapeutics worth $63,784,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Manchester Capital Management LLC lifted its position in shares of Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock worth $30,000 after buying an additional 156 shares in the last quarter. Newbridge Financial Services Group Inc. purchased a new position in Sarepta Therapeutics in the 4th quarter valued at about $36,000. Steward Partners Investment Advisory LLC grew its stake in shares of Sarepta Therapeutics by 164.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock valued at $38,000 after acquiring an additional 194 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its position in shares of Sarepta Therapeutics by 95.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock worth $54,000 after acquiring an additional 216 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on SRPT. Oppenheimer reduced their target price on Sarepta Therapeutics from $184.00 to $123.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. HC Wainwright restated a "neutral" rating and issued a $40.00 target price on shares of Sarepta Therapeutics in a research note on Thursday. Needham & Company LLC reduced their price target on shares of Sarepta Therapeutics from $183.00 to $125.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Guggenheim decreased their price target on Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Finally, Piper Sandler cut their price objective on Sarepta Therapeutics from $110.00 to $70.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. Six analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Sarepta Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $122.61.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock traded down $1.26 during trading hours on Thursday, reaching $38.79. The stock had a trading volume of 3,740,612 shares, compared to its average volume of 1,775,304. Sarepta Therapeutics, Inc. has a twelve month low of $34.10 and a twelve month high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The firm has a market capitalization of $3.81 billion, a PE ratio of 31.03 and a beta of 0.85. The firm has a 50-day simple moving average of $56.56 and a 200-day simple moving average of $95.81.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The business had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. During the same quarter in the prior year, the firm posted $0.73 earnings per share. The business's quarterly revenue was up 80.2% on a year-over-year basis. As a group, equities analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the sale, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. The trade was a 8.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 7.70% of the stock is currently owned by insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.